344 related articles for article (PubMed ID: 28830923)
61. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
62. Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.
Yadav V; Chen SH; Yue YG; Buchanan S; Beckmann RP; Peng SB
Pharmacol Ther; 2015 May; 149():139-49. PubMed ID: 25550229
[TBL] [Abstract][Full Text] [Related]
63. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
Mikoshiba A; Ashida A; Sakaizawa K; Kiniwa Y; Okuyama R
J Dermatol Sci; 2020 Mar; 97(3):172-178. PubMed ID: 31987696
[TBL] [Abstract][Full Text] [Related]
64. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.
Kannengiesser C; Brookes S; del Arroyo AG; Pham D; Bombled J; Barrois M; Mauffret O; Avril MF; Chompret A; Lenoir GM; Sarasin A; ; Peters G; Bressac-de Paillerets B
Hum Mutat; 2009 Apr; 30(4):564-74. PubMed ID: 19260062
[TBL] [Abstract][Full Text] [Related]
65. Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens.
Kato S; Okamura R; Adashek JJ; Khalid N; Lee S; Nguyen V; Sicklick JK; Kurzrock R
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33427211
[TBL] [Abstract][Full Text] [Related]
66. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
Ceha HM; Nasser I; Medema RH; Slebos RJ
Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
[TBL] [Abstract][Full Text] [Related]
67. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.
Barton KL; Misuraca K; Cordero F; Dobrikova E; Min HD; Gromeier M; Kirsch DG; Becher OJ
PLoS One; 2013; 8(10):e77639. PubMed ID: 24098593
[TBL] [Abstract][Full Text] [Related]
68. A Preexisting Rare
Romano G; Chen PL; Song P; McQuade JL; Liang RJ; Liu M; Roh W; Duose DY; Carapeto FCL; Li J; Teh JLF; Aplin AE; Chen M; Zhang J; Lazar AJ; Davies MA; Futreal PA; Amaria RN; Zhang DY; Wargo JA; Kwong LN
Cancer Discov; 2018 May; 8(5):556-567. PubMed ID: 29496665
[TBL] [Abstract][Full Text] [Related]
69. Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
Kishimoto I; Mitomi H; Ohkura Y; Kanazawa H; Fukui N; Watanabe M
J Surg Oncol; 2008 Jul; 98(1):60-6. PubMed ID: 18484097
[TBL] [Abstract][Full Text] [Related]
70. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
VanArsdale T; Boshoff C; Arndt KT; Abraham RT
Clin Cancer Res; 2015 Jul; 21(13):2905-10. PubMed ID: 25941111
[TBL] [Abstract][Full Text] [Related]
71. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments.
Witkiewicz AK; Knudsen KE; Dicker AP; Knudsen ES
Cell Cycle; 2011 Aug; 10(15):2497-503. PubMed ID: 21775818
[TBL] [Abstract][Full Text] [Related]
72. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors.
Kovar H; Jug G; Aryee DN; Zoubek A; Ambros P; Gruber B; Windhager R; Gadner H
Oncogene; 1997 Oct; 15(18):2225-32. PubMed ID: 9393981
[TBL] [Abstract][Full Text] [Related]
73. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ
Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
[TBL] [Abstract][Full Text] [Related]
74. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.
van der Velden PA; Metzelaar-Blok JA; Bergman W; Monique H; Hurks H; Frants RR; Gruis NA; Jager MJ
Cancer Res; 2001 Jul; 61(13):5303-6. PubMed ID: 11431374
[TBL] [Abstract][Full Text] [Related]
75. The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma.
Yu J; Yu J; Wu X; Guo Q; Yin T; Cheng Z; Dai J; Kong Y; Guo J
Clin Sci (Lond); 2020 Jan; 134(2):193-205. PubMed ID: 31919521
[TBL] [Abstract][Full Text] [Related]
76. CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.
Salvador-Barbero B; Álvarez-Fernández M; Zapatero-Solana E; El Bakkali A; Menéndez MDC; López-Casas PP; Di Domenico T; Xie T; VanArsdale T; Shields DJ; Hidalgo M; Malumbres M
Cancer Cell; 2020 Mar; 37(3):340-353.e6. PubMed ID: 32109375
[TBL] [Abstract][Full Text] [Related]
77. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.
Kong Y; Si L; Li Y; Wu X; Xu X; Dai J; Tang H; Ma M; Chi Z; Sheng X; Cui C; Guo J
Clin Cancer Res; 2016 Feb; 22(4):1018-27. PubMed ID: 26490311
[TBL] [Abstract][Full Text] [Related]
78. CDK4/6 inhibitors in breast cancer.
Dukelow T; Kishan D; Khasraw M; Murphy CG
Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
[TBL] [Abstract][Full Text] [Related]
79. The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
Du Q; Guo X; Wang M; Li Y; Sun X; Li Q
J Hematol Oncol; 2020 May; 13(1):41. PubMed ID: 32357912
[TBL] [Abstract][Full Text] [Related]
80. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
